Mon.Jan 08, 2024

article thumbnail

Opinion: Americans are obsessed with health and fitness tracking. It’s time for a data diet

STAT

Turn on your TV or open a web browser this January, and you’ll be bombarded with ads for fitness trackers, smart scales, health apps, and other digital innovations promising to streamline your journey to a happier and healthier you. It’s the time of year when we’re most susceptible to such messaging: Surveys show that at least one-third of our New Year’s resolutions focus on exercising, losing weight, or eating better.

341
341
article thumbnail

Regulatory twists and turns are coming for biopharma in 2024

PharmaVoice

New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

189
189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: At JPM, biotech’s most prolific dealmaker sees a rosy 2024 for acquisitions

STAT

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years. That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech.

290
290
article thumbnail

SAEM Clinical Images Series: A Lethal Combination of Skin and Lung Findings

ALiEM - Pharm Pearls

A 49-year-old female with a past medical history of recurrent diverticulitis initially presented with one month of shortness of breath and a minor nonproductive cough for which she was started on doxycycline by her primary care provider. She then developed a rash on her chest, upper back, and face. Antibiotics were switched to amoxicillin and azithromycin.

Hospitals 152
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: CVS Health sees Medicare Advantage patients seek more care, eating into profits

STAT

Medicare Advantage members continue to go to the doctor and get health care procedures a lot more than predicted, CVS Health executives said at the J.P. Morgan Healthcare Conference on Monday. A persistent theme for health insurance companies throughout 2023 has been their Medicare Advantage members using more care than their actuaries projected, which has been eating into the profits they get from federally funded health care premiums.

article thumbnail

JPM: Four ways FDA is seeking to buoy gene therapy

pharmaphorum

Dr Peter Marks, director of the FDA Center for Biologics Evaluation and Research told a packed house in San Francisco for JPM that FDA wants to support gene therapies in 2024.

138
138

More Trending

article thumbnail

Year of biotech layoffs leaves industry looking for spark

PharmaVoice

Small and mid-sized drugmakers shed at least 10,000 jobs in 2023, according to data compiled by BioPharma Dive, but recent deal, stock market momentum have brought some optimism.

130
130
article thumbnail

STAT+: Mayo Clinic partners with supercomputing startup Cerebras to build custom AI tools

STAT

SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday. The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P.

article thumbnail

How J&J is tackling a ‘secondary pandemic’ in the Black community

PharmaVoice

J&J is leading a grassroots effort to improve mental health access and care.

130
130
article thumbnail

STAT+: Hospitals try a new pitch to investors: other ways of making money

STAT

SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.

Hospitals 264
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job

BioPharma Dive

The chip maker struck a new deal with Amgen on Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.

128
128
article thumbnail

STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care

STAT

A group of academic hospitals and technology companies will form a new nonprofit venture to oversee a nationwide network of laboratories to test artificial intelligence tools designed for use in health care. The nonprofit will establish the laboratories at Mayo Clinic, Duke, Stanford, and other major universities and institutions around the country.

article thumbnail

How Quantum Computing Will Impact Pharma in 2024: Q&A With Erik Huestis, Partner at Foley Hoag

PharmExec

Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.

126
126
article thumbnail

UnitedHealth’s next physician acquisition & the January health insurance churn

STAT

You’re reading the web version of Health Care Inc.,  STAT’s weekly newsletter  following the flow of money in medicine.  Sign up  to get it in your inbox every Monday.  JPM24 is ~here~ The J.P. Morgan Healthcare Conference is exhausting and wildly expensive — a rather apt metaphor for the health care system itself.

Hospitals 246
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

This week in clinical trials: 2nd-5th January 2024

pharmaphorum

Stay up to date with the latest developments in clinical trials, including updates on Vicore, Mundipharma, Agios, Ultragenyx, EG 427, Orion, and MSD. Find out what these companies are working on and their potential impact on healthcare.

116
116
article thumbnail

STAT+: Boston Scientific acquires Axonics, urology company, for $3.7 billion

STAT

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year.

240
240
article thumbnail

Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi

BioPharma Dive

At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now ‘not an issue’ for treatment.

114
114
article thumbnail

STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves

STAT

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history. He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Servier will apply ‘digital twin’ tech to Parkinson’s drug

pharmaphorum

Servier has added a third digital twin project to its collaboration with AI specialist Aitia, trying to identify Parkinson's patients who will respond to its LRRK2 inhibitor in clinical trials.

112
112
article thumbnail

STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma

STAT

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.   The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference , extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

article thumbnail

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

pharmaphorum

Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships

111
111
article thumbnail

Opinion: Cost isn’t the only reason Medicare doesn’t cover Wegovy

STAT

Few medications have captured the national attention like Wegovy — and for good reason. In a country with a well-documented obesity epidemic, Wegovy and other members of a new type of weight-loss drug are highly effective: In clinical trials, people on Wegovy typically lose 15% of body weight , and a similar medication, retatrutide, has shown up to 24% weight loss.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

AstraZeneca Vice President, Head of Breast Cancer Franchise, Discusses Impact of Truqap Approval

PharmExec

In an interview with Pharmaceutical Executive associate editor Don Tracy, Ashley Gaines, VP, head of breast cancer franchise, discusses newly approved Truqap.

111
111
article thumbnail

STAT+: Merck to acquire Harpoon Therapeutics for $680 million

STAT

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.

Immunity 211
article thumbnail

12 Questions with Marcus West

pharmaphorum

This 12 Questions With Marcus West explores the 60 Seconds remote coaching app founder's journey into corporate coaching and how West realised his clients would improve faster if they dedicated themselves to ongoing microlearning in between coaching sessions.

111
111
article thumbnail

STAT+: Walgreens isn’t acquiring anytime soon, per CEO

STAT

Between Walgreens’ earnings call last week and its J.P. Morgan Healthcare Conference presentation on Monday, it’s becoming clear that the company won’t be acquiring anything anytime soon. “We are not cash rich right now. We’re not in a position where we can do large acquisitions, and I believe we’re not in a position where we need to [in order] to grow the company in a meaningfully responsible way on an earnings basis for the longer term,” said Ti

210
210
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Merck pays $680M for struggling cancer biotech Harpoon

BioPharma Dive

The acquisition will build out Merck’s pipeline of immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.

111
111
article thumbnail

STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug

STAT

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead. The deal includes up to another $400 million in payments if certain milestones are met. Aiolos was launched just last year , based in both San Francisco and London.

article thumbnail

Unveiling the Secrets of Patent Litigation and Settlements in Pharmaceuticals

Drug Patent Watch

The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the… The post Unveiling the Secrets of Patent Litigation and Settlements in Pharmaceuticals appeared first on DrugPatentWatch - Make Better Decisions.

111
111
article thumbnail

STAT+: Former Sage executives join biotech VC Cure Ventures

STAT

Cure Ventures , a Boston-based venture capital firm founded in 2021 by a trio of veteran biotech investors, has brought in two former executives from Sage Therapeutics to prepare them for investing in neuroscience startups. The VC firm has hired Jeff Jonas, Sage’s former chief executive, and Al Robichaud, Sage’s former chief scientific officer, as partners, the team told STAT exclusively.

Labelling 199
article thumbnail

AlcoChange app to help alcohol-related liver disease patients stay sober

Pharma Times

Over a three-month period, 57% of patients using the app remained sober

Hospitals 110